Sunday, October 26, 2014 8:17:47 PM
1. DCVax-Direct (Dendritic cells) is/are injected into a cancer tumor.
2. DCVax immediately secretes (releases) massive amounts of cytokines (natural chemicals) that kill tumor cells, create inflammation and signal the innate (early) immune system to respond. This is just the beginning.
3. The DCVax dendritic cells start nibbling on the dead tumor debris. Because these are special dendritic cells, the tumor cannot use its normal toolkit of different cytokines (natural chemicals) to stop the dendritic cell from ingesting this dead tumor debris. Just call them the teflon DCs.
4. After dining on the tumor debris, the dendritic cell processes the dead tissue into tinier fragments scientists call antigens, and the DC actually display these dead tumor parts (antigens) on the dendritic cell surface. Again, normally the tumor environment would stop or interfere with dendritic cells trying to process and display dead tumor debris (antigens), but not our DCVax dendritic cells. They are like super-mailmen undeterred by local lousy conditions, and intent on making their appointed rounds.
5. Now the dendritic cells escape the tumor micro environment laden heavy with a dense coating of tumor antigens on their surfaces. Again, here the DCVax dendritic cell carries far more antigens packed upon its surface than any common dendritic cell might.
6. Next, the dendritic cell literally crawls through the extracellular matrix toward a nearby lymph node. Again, the DCVax dendritic cell is not slowed by the prior tumor environment attempts to weaken it before its journey.
7. Upon arrival at the lymph node, most dendritic cells would have been previously weakened by chemicals released by the tumor microenvironment both inside and outside the tumor; instead, the DCVax dendritic cell is still completely able to fully/hyper activate t-cells and b-cells to multiply and attack the intended target.
8. These t-cells and b-cells are so well instructed that they immediately proliferate into the millions and seek out tumor cells throughout the body.
9. The primary tumor, now weakened by the dendritic cytokines and innate immune system, is attacked by the SUPER t-cells and b-cells. Next, other tumors throughout the body are likewise attacked.
10. These members of the adaptive immune system are not fooled or blocked by the tumor, as non-DCvax activated t and b-cells might otherwise be. They finish off the tumors and store their memory in long lived memory cells that will attack should they try to return.
Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2024 09:24:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • SBC • Nov 7, 2024 7:00 AM